
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Couch in Crisis
History of Psychiatry
On DSM-5
Residents Blog
Tales From the New Asylum
Early Career Corner
All Blogs
Subscribe to our Blog Feed




